MHRA (UK) approves Kerendia to treat chronic kidney disease associated with type 2 diabetes in adults.- Bayer
Bayer has received authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA) for the use of Kerendia (finerenone) (10mg or 20mg) in Great Britain.
The novel, non-steroidal oral medicine is used to treat chronic kidney disease associated with type 2 diabetes in adults. It is already approved in the U.S. and the European Union, and regulatory filings in other regions are underway or planned. The MHRA’s approval is based on the results of the pivotal Phase III FIDELIO-DKD study, which investigated the efficacy of finerenone on kidney and cardiovascular outcomes in 5,734 adult patients. The result was published in the New England Journal of Medicine in October 2020.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins